Drug intelligence / Profile preview

Q-1901

Development stage: Unknown
Lead developer: QureBio

Overview

Q-1901 is a biological product under development by Qurebio for the treatment of neoplasms (cancers). As of March 2025, it remains in the discovery phase and has not entered clinical trials. The specific mechanism of action, molecular target(s), modality details, and route(s) of administration have not been publicly disclosed. No additional synonyms, brand names, or alternative designations are reported for this agent. The drug is being developed primarily in China by Qurebio Ltd., with no evidence of manufacturing or development partnerships with other companies at this stage[1][3][2].

Beyond the preview

Go deeper on Q-1901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q-1901.

Explore the full profile